The product portfolio consists of well-established pharmaceuticals such as Kavepenin, Heracillin, Kalcipos, and TrioBe. The acquisition is said to strengthen Meda’s home base in Sweden, and new product opportunities from Recip’s product portfolio can be commercialized outside the Nordics. Considerable synergy effects are also expected.
The acquisition price for all shares in Recip AB was SEK2.65 billion on a debt-free basis plus SEK5.7 million newly issued shares in Meda AB. The net debt that Meda took over totaled SEK832 million. Meda’s cash payment was SEK1.81 billion, totally financed within existing credit facilities. The price for the newly issued shares was set at SEK86.25 per share.